Merit Medical Systems (NASDAQ:MMSI) Issues FY 2026 Earnings Guidance

Merit Medical Systems (NASDAQ:MMSI) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 4.250-4.350 for the period, compared to the consensus estimate of 3.980. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Analyst Ratings Changes

MMSI has been the subject of several recent analyst reports. Barrington Research set a $114.00 price objective on shares of Merit Medical Systems in a research report on Friday. Citigroup reaffirmed an “outperform” rating on shares of Merit Medical Systems in a research report on Monday, April 20th. Canaccord Genuity Group set a $94.00 price target on shares of Merit Medical Systems in a research report on Friday. Piper Sandler upped their price objective on shares of Merit Medical Systems from $96.00 to $106.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Wells Fargo & Company lifted their target price on Merit Medical Systems from $74.00 to $83.00 and gave the stock an “equal weight” rating in a research report on Friday. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $100.30.

Merit Medical Systems Stock Performance

Shares of Merit Medical Systems stock traded up $1.66 during trading hours on Friday, hitting $85.01. 2,200,989 shares of the company were exchanged, compared to its average volume of 760,694. Merit Medical Systems has a 1 year low of $59.74 and a 1 year high of $94.75. The company has a current ratio of 5.08, a quick ratio of 3.46 and a debt-to-equity ratio of 0.45. The business has a 50-day moving average of $69.87 and a 200-day moving average of $71.78. The stock has a market capitalization of $5.07 billion, a price-to-earnings ratio of 35.13, a P/E/G ratio of 2.59 and a beta of 0.52.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.23. The firm had revenue of $418.84 million during the quarter, compared to the consensus estimate of $405.25 million. Merit Medical Systems had a return on equity of 13.97% and a net margin of 9.22%.The company’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period last year, the company earned $1.01 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. As a group, analysts expect that Merit Medical Systems will post 3.62 EPS for the current fiscal year.

Insider Buying and Selling at Merit Medical Systems

In other news, Director Lynne N. Ward sold 5,000 shares of Merit Medical Systems stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $62.61, for a total value of $313,050.00. Following the sale, the director owned 7,809 shares of the company’s stock, valued at $488,921.49. The trade was a 39.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Brian G. Lloyd purchased 2,000 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were purchased at an average price of $62.62 per share, for a total transaction of $125,240.00. Following the completion of the purchase, the insider owned 2,000 shares of the company’s stock, valued at approximately $125,240. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.70% of the stock is currently owned by company insiders.

Merit Medical Systems News Summary

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q2 results exceeded expectations: Merit reported revenue of $418.8 million, up 9.5% year over year and above the $405.3 million consensus estimate. Non-GAAP EPS rose 18% to $1.19, beating estimates of $0.96; GAAP operating margin also improved to 14.4% from 12.3%. Merit Medical Reports Second Quarter 2026 Results and Updates Full-Year 2026 Guidance
• Positive Sentiment: 2026 guidance was raised: Management now expects full-year adjusted EPS of $4.25-$4.35, above the $3.98 analyst consensus. Broad-based product growth, revenue gains and expanding margins supported the improved outlook. MMSI Q2 Earnings, Revenues Beat Estimates; 2026 Guidance Raised
• Positive Sentiment: Analyst targets moved higher: Needham raised its target to $101 and maintained a Buy rating; BTIG lifted its target to $105 and maintained Buy; and JPMorgan raised its target to $95 with an Overweight rating. These revisions indicate increased confidence in Merit’s growth and earnings trajectory. Analysts Increase Forecasts After Strong Q2 Results
• Neutral Sentiment: Analyst opinion remains mixed: Wells Fargo raised its target to $83 but retained an Equal Weight rating, leaving its target below the stock’s recent trading level. Wells Fargo Raises Merit Medical Price Target
• Negative Sentiment: Cash generation weakened: Year-to-date operating cash flow fell 11% to $110.0 million, while free cash flow declined 14% to $76.6 million, a potential concern despite the strong earnings performance. Merit Medical Second Quarter Results

Institutional Trading of Merit Medical Systems

Hedge funds have recently modified their holdings of the business. Corient Private Wealth LLC grew its holdings in Merit Medical Systems by 99.4% during the fourth quarter. Corient Private Wealth LLC now owns 6,312 shares of the medical instruments supplier’s stock worth $557,000 after acquiring an additional 3,146 shares during the period. Alberta Investment Management Corp purchased a new stake in shares of Merit Medical Systems during the 4th quarter worth $1,428,000. Mercer Global Advisors Inc. ADV boosted its position in shares of Merit Medical Systems by 36.8% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 3,540 shares of the medical instruments supplier’s stock worth $312,000 after purchasing an additional 952 shares in the last quarter. State of Tennessee Department of Treasury grew its stake in shares of Merit Medical Systems by 10.4% during the 4th quarter. State of Tennessee Department of Treasury now owns 28,492 shares of the medical instruments supplier’s stock worth $2,310,000 after purchasing an additional 2,689 shares during the period. Finally, Fuller & Thaler Asset Management Inc. increased its holdings in shares of Merit Medical Systems by 12.7% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock valued at $183,137,000 after purchasing an additional 234,682 shares in the last quarter. 99.66% of the stock is owned by institutional investors and hedge funds.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.